X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the license agreement, Alterity grants the entire rights to the AH patent as well as an exclusive worldwide license to develop and commercialize both AH and PBT2 (acyl hydrazone) in Alzheimer’s disease (AD).
Lead Product(s): PBT2
Therapeutic Area: Neurology Product Name: PBT2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Professor Colin Masters
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2023
Details:
PBT2 is a low molecular weight drug candidate, orally bioavailable, crosses the blood-brain barrier, it has demonstrated efficacy in individuals with alzheimer’s disease.
Lead Product(s): PBT2
Therapeutic Area: Neurology Product Name: PBT2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
The licensed technology combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. This is an opportunity for Alterity to further leverage its investment in PBT2.
Lead Product(s): PBT2
Therapeutic Area: Infections and Infectious Diseases Product Name: PBT2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alterity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
